Skip to main content
Kesimpta

Please select your country (language)

Austria (Deutsch)

Belgium (Nederlands)

Denmark (Dansk)

France (Français)

Iceland (Islenska)

Lithuania (Lietuvių kalba)

Malta (Malti)

Portugal (Português)

Spain (Español)

Bulgaria (Български)

Croatia (Hrvatski)

Estonia (Eesti keel)

Germany (Deutsch)

Ireland (English)

Luxembourg (Français)

The Netherlands (Nederlands)

Romania (Română)

Sweden (Svenska)

Belgium (Français)

Cyprus (Ελληνικά)

Finland (suomi)

Greece (Ελληνικά)

Italy (Italiano)

Luxembourg (German)

Norway (Norsk)

Slovakia (Slovenčina)

UK-Northern Ireland (English)
 

Belgium (Deutsch)

Czech Republic (Česky)

Finland (Svenska)

Hungary (Magyar)

Latvia (Latviešu valoda)

Malta (English)

Poland (Polski)

Slovenia (slovenščina)

Legal Ireland
  • Terms of Use
  • Cookie Policy
  • Cookie Settings
© 2025 Novartis BE2208177152 août 2022

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please refer to the Package Leaflet for more information.

Reporting side effects: If you get side effects with any medication you are taking, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed in the information leaflet that comes in the pack.
      ▼The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects.